The objective of this proposal is to define the in vivo effectiveness of a melanoma-targeted nanoparticle for systemic therapeutic delivery. The approach is to utilize a ¿clinically experienced" fusogenic bilamellar invaginated vesicle nanoparticle (BIV NP) with a manually extruded DOTAP:cholesterol formulation for the systemic delivery of DNA and RNAi expression plasmids. This will involve the preclinical validation of two recent technological advances: reversible masking and tumor-specific ligand decoration. Reversible masking is a non-toxic alternative to pegylation and involves transient coating with small, uncharged, lipids to bypass non-targeted organs and re-exposure of charge at the target cells for enhanced transfection. Further, the BIV NP will be decorated with low mw, non-immunogenic beta-turn "semi-peptidic" small molecules that mimic secondary structure motifs found at hot-spots in protein-ligand interactions. The small molecule candidate is selected by screening with melanoma cell lines and patient primary cultures for enhanced transgene expression. The project will include: 1) prioritization of low mw ligands that promote BIV-delivered transgene expression; 2) demonstration in nu/nu-hu melanoma xenograft models of the enhanced expression and anti-tumor activity of BIV NPs with pre-established anti-oncogene activities (bi-shSTMN1 payload); and 3) implementation of a GMP manufacturing process for the formulated melanoma-targeted, reversibly-masked bi-shSTMN1-BIV product. These activities will pave the way for future safety/toxicology studies and early phase clinical trials.
NIH Spending Category: Bioengineering; Cancer; Gene Therapy; Genetics; Nanotechnology
Project Terms: Bypass; Cell Line; Cells; Charge; Cholesterol; Clinical Trials; DNA; DNA delivery; Drug Formulations; Effectiveness; experience; Future; Hot Spot; improved; in vivo; Ligands; Lipids; manufacturing process; Masks; melanoma; Melanoma Cell; nanoparticle; Organ; Patients; Phase; Plasmids; pre-clinical; Process; Proteins; RNA Interference; Safety; Screening procedure; Small Business Innovation Research Grant; small molecule; Structure; Therapeutic; Toxicology; Transfection; transgene expression; Treatment Efficacy; tumor; Tumor Suppressor Genes; Validation; Vesicle; Xenograft Model
